A team within Blueprint Medicines' global Medical Affairs organization is collaborating with research partners to use ‘real-world’ evidence from numerous sources to help providers more quickly identify and diagnose patients with systemic mastocytosis.
With achieving approvals for two medicines and advancing a broad pipeline of investigational therapies, we have a proven track record of discovering, developing and commercializing innovative medicines that target root causes of disease.
View our pipeline ______________ View our approved medicines ___________ Read about our core programs
Our world-leading expertise in mast cell and cancer biology powers the relentless development of transformational medicines. We believe our progress in the clinic reflects the power of our platform to rapidly and reproducibly pursue highly selective medicines against diverse, difficult-to-drug targets.
Read more about our scientific platform
Patients are at the center of Blueprint Medicines’ mission to discover, develop and deliver innovative medicines that address significant medical needs. From conducting rigorous clinical trials and supporting medical research, to successfully registering our medicines with global health authorities and providing a robust U.S. patient support program for our approved medicines through YourBlueprint®, we aim to bring innovative treatments to the greatest number of patients who may benefit, as quickly and responsibly as possible.
Learn about our ongoing clinical trials Read our policy on early access Find out about our U.S. patient support program, YourBlueprint® Learn how we support investigator sponsored trials1-888-BLU-PRNT (1-888-258-7768)
+31 85 064 4001
YourBlueprint® patient support program
1-888-BLUPRNT (1-888-258-7768)
Monday-Friday, 8 a.m. to 8 p.m. ET
YourBlueprint.com or YourBlueprint.com/HCP
“Our team is composed of scientific pioneers with significant expertise across the R&D continuum, from drug discovery to global clinical development. Together, we aim to rapidly design and develop transformative medicines for patients in need.”Becker Hewes, M.D., Chief Medical Officer
